New drug duo shows promise for tough bile duct cancer

NCT ID NCT04781192

First seen Jan 26, 2026 · Last updated May 10, 2026 · Updated 14 times

Summary

This study tests whether combining two drugs, regorafenib and durvalumab, can help people with advanced bile duct cancer that has stopped responding to chemotherapy. About 40 participants will receive the combination to see if it slows tumor growth and how safe it is. The goal is to control the disease, not cure it, as ongoing treatment is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • The University of Kansas Medical Center

    Westwood, Kansas, 66205, United States

  • The University of Kansas Medical Center

    North Kansas City, Missouri, 64116, United States

  • University of Kansas Cancer Center - Lee's Summit

    Lee's Summit, Missouri, 64064, United States

  • University of Kansas Cancer Center - North

    Kansas City, Missouri, 64154, United States

  • University of Kansas Cancer Center - Overland Park

    Overland Park, Kansas, 66210, United States

Conditions

Explore the condition pages connected to this study.